LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Forte Biosciences, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERFBRX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / FBRX COVERAGE

What’s moving Forte Biosciences, Inc. now

Current reporting with the operating signal separated from the noise.

01
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to ...

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to ...

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

The story matters when it changes Forte Biosciences, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest FBRX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-11 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-14 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-31 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-27 · Period 2026-07-26SEC ↗8-KMaterial company eventFiled 2026-07-09 · Period 2026-07-09SEC ↗8-KMaterial company eventFiled 2026-06-02 · Period 2026-05-29SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-29 · Period 2026-05-29SEC ↗SC TO-COfficial SEC filingFiled 2026-07-28SEC ↗
EARNINGS / QUARTERLY TRACKER

Forte Biosciences, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.